CU24181B1 - POLIPÉPTIDOS DERIVADOS DEL TGFß - Google Patents

POLIPÉPTIDOS DERIVADOS DEL TGFß

Info

Publication number
CU24181B1
CU24181B1 CU20120158A CU20120158A CU24181B1 CU 24181 B1 CU24181 B1 CU 24181B1 CU 20120158 A CU20120158 A CU 20120158A CU 20120158 A CU20120158 A CU 20120158A CU 24181 B1 CU24181 B1 CU 24181B1
Authority
CU
Cuba
Prior art keywords
tgfß
derived polypeptides
polypeptides
derived
tgfß derived
Prior art date
Application number
CU20120158A
Other languages
English (en)
Other versions
CU20120158A7 (es
Inventor
Osorio Ángel De Jesús Corria
Monzón Kalet León
Portilla Tania Carmenate
Meriño Amaury Pupo
Rodríguez Saumel Pérez
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24181(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CU20120158A priority Critical patent/CU24181B1/es
Priority to US14/440,627 priority patent/US9701730B2/en
Priority to UAA201505566A priority patent/UA115678C2/uk
Priority to NZ707850A priority patent/NZ707850A/en
Priority to ES13805228T priority patent/ES2857176T3/es
Priority to AU2013344022A priority patent/AU2013344022B2/en
Priority to CN201380058181.7A priority patent/CN104902916B/zh
Priority to EP13805228.7A priority patent/EP2918284B1/en
Priority to EA201590914A priority patent/EA031990B1/ru
Priority to JP2015540045A priority patent/JP6298823B2/ja
Priority to BR112015010145-3A priority patent/BR112015010145B1/pt
Priority to PCT/CU2013/000007 priority patent/WO2014071894A1/es
Priority to MX2015005875A priority patent/MX366060B/es
Priority to MYPI2015701369A priority patent/MY173078A/en
Priority to SG11201502980VA priority patent/SG11201502980VA/en
Priority to PE2015000549A priority patent/PE20150890A1/es
Priority to CA2887455A priority patent/CA2887455C/en
Priority to KR1020157011131A priority patent/KR102093494B1/ko
Priority to JOP/2013/0317A priority patent/JO3502B1/ar
Priority to TW102140494A priority patent/TWI615404B/zh
Priority to ARP130104078A priority patent/AR093391A1/es
Publication of CU20120158A7 publication Critical patent/CU20120158A7/es
Priority to TNP2015000129A priority patent/TN2015000129A1/fr
Priority to PH12015500807A priority patent/PH12015500807A1/en
Priority to CO15095702A priority patent/CO7400865A2/es
Priority to IL238621A priority patent/IL238621B/en
Priority to CL2015001252A priority patent/CL2015001252A1/es
Priority to ZA2015/04462A priority patent/ZA201504462B/en
Priority to HK16101766.2A priority patent/HK1213781A1/zh
Publication of CU24181B1 publication Critical patent/CU24181B1/es
Priority to JP2018031896A priority patent/JP6608473B2/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CU20120158A 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß CU24181B1 (es)

Priority Applications (29)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PE2015000549A PE20150890A1 (es) 2012-11-09 2013-10-30 POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS
SG11201502980VA SG11201502980VA (en) 2012-11-09 2013-10-30 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
CA2887455A CA2887455C (en) 2012-11-09 2013-10-30 Polypeptides derived from tgf.beta. and uses thereof
UAA201505566A UA115678C2 (uk) 2012-11-09 2013-10-30 МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ
ES13805228T ES2857176T3 (es) 2012-11-09 2013-10-30 Polipéptidos derivados de TGF y usos de los mismos
AU2013344022A AU2013344022B2 (en) 2012-11-09 2013-10-30 Polypeptides derived from TGFBETA and uses thereof
CN201380058181.7A CN104902916B (zh) 2012-11-09 2013-10-30 衍生自TGFβ的多肽及其用途
EP13805228.7A EP2918284B1 (en) 2012-11-09 2013-10-30 Polypeptides derived from tgf and uses thereof
EA201590914A EA031990B1 (ru) 2012-11-09 2013-10-30 МУТАНТНЫЕ ПОЛИПЕПТИДЫ TGFβ И ИХ ПРИМЕНЕНИЕ
JP2015540045A JP6298823B2 (ja) 2012-11-09 2013-10-30 TGFβに由来するポリペプチド及びその使用
BR112015010145-3A BR112015010145B1 (pt) 2012-11-09 2013-10-30 Polipeptídeo, e, composição farmacêutica para o tratamento de câncer
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS
MX2015005875A MX366060B (es) 2012-11-09 2013-10-30 Polipéptidos derivados de tgfbeta y sus usos.
MYPI2015701369A MY173078A (en) 2012-11-09 2013-10-30 Tgf?-derived polypeptides and uses thereof
US14/440,627 US9701730B2 (en) 2012-11-09 2013-10-30 TGFβ-derived polypeptides and uses thereof
KR1020157011131A KR102093494B1 (ko) 2012-11-09 2013-10-30 TGFβ-유래 폴리펩티드 및 이들의 용도
NZ707850A NZ707850A (en) 2012-11-09 2013-10-30 Polypeptides derived from tgfβ and uses thereof
JOP/2013/0317A JO3502B1 (ar) 2012-11-09 2013-11-03 البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها
ARP130104078A AR093391A1 (es) 2012-11-09 2013-11-07 POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS
TW102140494A TWI615404B (zh) 2012-11-09 2013-11-07 轉變生長因子β(TGFβ)衍生之多肽類及彼等之用途
TNP2015000129A TN2015000129A1 (en) 2012-11-09 2015-04-03 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
PH12015500807A PH12015500807A1 (en) 2012-11-09 2015-04-13 Tgf�-derived polypeptides and uses thereof
CO15095702A CO7400865A2 (es) 2012-11-09 2015-04-28 Polipeptidos derivados del tgfbeta y sus usos
IL238621A IL238621B (en) 2012-11-09 2015-05-04 Polypeptides derived from tgfß– and their uses
CL2015001252A CL2015001252A1 (es) 2012-11-09 2015-05-08 Polipéptido que antagoniza la actividad de los ligando tgf beta naturales mediada por el receptor alk5; composición farmacéutica que lo comprende; y sus usos.
ZA2015/04462A ZA201504462B (en) 2012-11-09 2015-06-08 TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
HK16101766.2A HK1213781A1 (zh) 2012-11-09 2016-02-18 衍生自 β的多肽及其用途
JP2018031896A JP6608473B2 (ja) 2012-11-09 2018-02-26 TGFβに由来するポリペプチド及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Publications (2)

Publication Number Publication Date
CU20120158A7 CU20120158A7 (es) 2014-06-27
CU24181B1 true CU24181B1 (es) 2016-04-25

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Country Status (28)

Country Link
US (1) US9701730B2 (es)
EP (1) EP2918284B1 (es)
JP (2) JP6298823B2 (es)
KR (1) KR102093494B1 (es)
CN (1) CN104902916B (es)
AR (1) AR093391A1 (es)
AU (1) AU2013344022B2 (es)
BR (1) BR112015010145B1 (es)
CA (1) CA2887455C (es)
CL (1) CL2015001252A1 (es)
CO (1) CO7400865A2 (es)
CU (1) CU24181B1 (es)
EA (1) EA031990B1 (es)
ES (1) ES2857176T3 (es)
HK (1) HK1213781A1 (es)
IL (1) IL238621B (es)
JO (1) JO3502B1 (es)
MX (1) MX366060B (es)
MY (1) MY173078A (es)
NZ (1) NZ707850A (es)
PE (1) PE20150890A1 (es)
PH (1) PH12015500807A1 (es)
SG (1) SG11201502980VA (es)
TN (1) TN2015000129A1 (es)
TW (1) TWI615404B (es)
UA (1) UA115678C2 (es)
WO (1) WO2014071894A1 (es)
ZA (1) ZA201504462B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7079779B2 (ja) * 2016-11-18 2022-06-02 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 操作されたtgfベータ単量体およびtgfベータシグナル伝達のためのそれらの使用
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
CA2575278A1 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
EP1838730A4 (en) * 2005-01-11 2015-04-29 Molecular Logix Inc PAN-HER ANTAGONISTS AND METHODS OF USE
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
MX2012012229A (es) * 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.

Also Published As

Publication number Publication date
TW201431875A (zh) 2014-08-16
EA201590914A1 (ru) 2015-09-30
BR112015010145A2 (es) 2017-08-22
PH12015500807A1 (en) 2015-06-08
CL2015001252A1 (es) 2015-07-17
JO3502B1 (ar) 2020-07-05
MY173078A (en) 2019-12-25
US9701730B2 (en) 2017-07-11
CA2887455A1 (en) 2014-05-15
EA031990B1 (ru) 2019-03-29
CN104902916B (zh) 2018-04-13
AR093391A1 (es) 2015-06-03
CA2887455C (en) 2022-05-17
JP2015535000A (ja) 2015-12-07
MX366060B (es) 2019-06-26
UA115678C2 (uk) 2017-12-11
NZ707850A (en) 2019-08-30
ZA201504462B (en) 2018-11-28
EP2918284A1 (en) 2015-09-16
AU2013344022B2 (en) 2016-12-15
IL238621B (en) 2019-12-31
TWI615404B (zh) 2018-02-21
MX2015005875A (es) 2015-09-10
JP6608473B2 (ja) 2019-11-20
TN2015000129A1 (en) 2016-10-03
JP2018111703A (ja) 2018-07-19
AU2013344022A1 (en) 2015-05-28
PE20150890A1 (es) 2015-06-10
US20150284441A1 (en) 2015-10-08
BR112015010145B1 (pt) 2022-06-07
ES2857176T3 (es) 2021-09-28
HK1213781A1 (zh) 2016-07-15
KR20150083848A (ko) 2015-07-20
JP6298823B2 (ja) 2018-03-20
WO2014071894A1 (es) 2014-05-15
KR102093494B1 (ko) 2020-03-26
CO7400865A2 (es) 2015-09-30
SG11201502980VA (en) 2015-06-29
CN104902916A (zh) 2015-09-09
EP2918284B1 (en) 2021-02-17
CU20120158A7 (es) 2014-06-27
IL238621A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
SMT201700053B (it) Derivato del cicloalcano
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
UA24760S (uk) Шрифт
DK2825157T3 (da) Aminosyrelipider
DK2831122T3 (da) Anthocyanidin-kompleks
CL2014002180A1 (es) Peptidos antomicrobianos
DE112012006214T8 (de) Wulstringwickler
DE112012005566T8 (de) Seltenerdnanoverbundmagnet
FI20126082A (fi) Kaasunvaihtoventtiilijärjestely
DK2885638T3 (da) Molekylenet
DK2858657T3 (da) Feijoafrugtekstrakt
FI20126157A (fi) Laajentumistila
FI20125844A (fi) Talotekniikkamoduuli
ES1077590Y (es) Columbario
CU24181B1 (es) POLIPÉPTIDOS DERIVADOS DEL TGFß
DE102013212400A8 (de) Abdeckplattenstützbaugruppe
FI20126108A (fi) Pankkorakenne
DK2897570T3 (da) Spin-elueringsrør
FI9909U1 (fi) Kiinnitysjärjestely
FI20126064A (fi) Leijupetilämmönvaihdin

Legal Events

Date Code Title Description
FG Grant of patent